Shiga toxin-producing Escherichia coli (STEC) is a notable concern because it can cause Hemolytic- Uremic Syndrome (HUS). Our firm has cumulative experience in the creation of decent STEC-HUS vaccines. Our ultimate aim is to provide one-stop solutions to global pharmaceutical firms.
Overview of STEC-Hemolytic-uremic Syndrome
Escherichia coli that produces Shiga toxins (STEC) are responsible for causing great public health disruption globally as it can also lead to a serious complication called Shiga toxin-induced hemolytic uremic syndrome (STEC-HUS). This is a condition that involves the triad of microangiopathic hemolytic anemia, thrombocytopenia and an acute kidney injury.
STEC-HUS is associated with certain STEC strains, most noticeably E. coli O157:H7 which produces potent Shiga toxins, Stx1 and Stx2 . These toxins inflict damage to the endothelial cells of blood vessels and cause recruitment of platelets to the injury site and later thrombus formation and post organ injury, commonly in the kidney.
Fig.1 Schematic diagram of STEC-HUS pathogenesis and therapeutic targets. (Liu Y., et al., 2022)
Vaccine Development for STEC-HUS
The urged creation of a vaccine directed against SETC-HUS is reasonable considering the possible complications of the disease including chronic kidney disease, and neurological damage. The purpose of a vaccine against SETC-HUS is to induce an adequate immune response so that STEC particles do not attach and colonize the gut, and Shiga toxins are not synthesized and secreted.
Vaccine against STEC HUS infection attempts collapsible strategies mentioned below:
- Attenuated Bacteria: Employing live but weakened forms of the bacteria STEC in causing immune response without inflicting any disease.
- Recombinant Proteins: Engineering of proteins that imitate some portions of the STEC bacteria for immunity purposes.
- Polysaccharide Conjugates: The attaching of sugar molecules onto proteins for better immune responses in infants and young children.
Therapeutics Development for STEC-HUS
In the last few years, different means of dealing with the Shiga toxins have been promising. These include:
- Anti-Shiga Toxin Antibodies: These drugs are intended to interact with the toxins present in the circulation to inactivate those.
- Toxin Receptor Inhibitors: These are Gb3Cer inhibitors which antagonize the receptors which Shiga toxins need in order to infect the cells.
- Retro-2: A substrate that inhibits the intracellular movement of Shiga toxins so that they can have no cytotoxic effects.
Table 1 Clinical trials on the therapeutics of STEC-HUS. (Liu Y., et al., 2022)
| Identifier |
Interventions |
Time Period |
Country |
| NCT00004465 |
SYNSORB Pk vs. placebo |
1997/7/27~2001/4/14 |
United States, Canada |
| SHIGATEC |
Shigamabs(cαStx1/cαStx2) vs. placebo |
2010/11~2011/2 |
Argentina, Chile, Peru |
| NCT01252199 |
cαStx1/cαStx2 vs. placebo |
2011/11~2013/2 |
Argentina, Chile, Peru |
| NCT01406288 |
HUS standard coverage care (including in ICU) |
2011/7~2012/3 |
France |
| NCT01410916 |
Eculizumab (Soliris®) vs. placebo |
2011/7~2012/6 |
Germany |
| NCT02205541 |
Eculizumab vs. placebo |
2015/6~2018/6 |
France |
| NCT02336516 |
Azithromycin vs. placebo |
2015/7~2021/4 |
France |
| ECUSTEC |
Eculizumab vs. placebo |
2016/12~2021/4 |
United Kingdom |
| NCT03388216 |
INM004 vs. placebo |
2017/12/16~2018/9/28 |
Argentina |
| NCT03776851 |
Erythropoietin (EPO) |
2019/1/1~2020/12/30 |
Argentina |
| NCT04132375 |
INM004 vs. placebo |
2019/7/17~2022/9/1 |
Argentina |
| NCT05219110 |
Hyperhydration vs. conservative fluid management |
2022/9/1~2027/8/31 |
United States, Canada |
Our Services
Our organization provides a STEC-HUS research service that is tailored to facilitate vaccine and therapy development. Below is a synopsis of the services that we provide that are delivered by competent researchers in world class facilities:
Infectious Disease Models
- STEC Induced Models
- Purified Stx2 Induced Models
- VTEC/VT2 Induced Models
- VT2 Induced Models
- Purified Stx1 and Stx2a Induced Models
- EHEC O104:H4 Induced Models
- O153/O157:H7 Induced Models
Our company is well equipped to fast track the development of groundbreaking STEC-HUS solutions through the integration of advanced infrastructure, unwavering dedication to innovation and remarkable scientific know-how. If our services are of interest, we invite you to contact us for additional details and to request an exact quote shall you require some of our services.
Reference
- Liu Yang, et al. "Diagnosis and treatment for Shiga toxin-producing Escherichia coli associated hemolytic uremic syndrome." Toxins 15.1 (2022): 10.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
